The DOI matches its Crossref record; 405 of the 405 references it cites were found in a registry or an index; 201 of the 354 sources its claims cite were checked for support.
Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells
Open accessAbstract
Liver fibrosis/cirrhosis, characterized by excessive deposition of extracellular matrix (ECM) and formation of fibrous scars, arises from chronic liver injury and poses a significant global health burden. Although liver transplantation remains the sole curative option, its application is limited by donor scarcity, immune rejection risks, and high costs. Cellular therapies, particularly those based on mesenchymal stromal cells (MSCs), have emerged as a promising alternative. This review comprehensively examines the therapeutic mechanisms and clinical efficacy of diverse cell therapies for liver cirrhosis, with a focus on MSC-based approaches. MSCs demonstrate multifaceted advantages, including immunomodulatory properties, anti-fibrotic effects (via hepatic stellate cell inhibition and ECM remodeling), promotion of hepatocyte regeneration, and mitigation of oxidative stress. Their low immunogenicity facilitates allogeneic transplantation, while their availability from multiple sources (e.g., bone marrow, umbilical cord, adipose tissue) supports scalable clinical application. We analyze 95 registered clinical trials (73 MSC-focused), highlighting consistent safety profiles but variable efficacy, influenced by factors such as cell source, preparation protocols, administration route, and patient heterogeneity. Key challenges include standardizing MSC production (donor selection, culture conditions, cryopreservation), optimizing delivery methods (intravenous vs. intrahepatic routes), and defining dosing regimens. Strategies to enhance MSC efficacy-such as genetic modification, biomaterial engineering, combinatorial therapies (e.g., with endothelial progenitor cells or macrophages), and MSC-derived extracellular vesicles-are critically evaluated. Future perspectives emphasize the need for large-scale randomized trials, single-cell technologies to resolve MSC heterogeneity, and organoid models to refine therapeutic protocols.
Overview
CoChat Summary
## TL;DR
This review argues that mesenchymal stromal cell (MSC) therapy is the most promising cell-based approach for liver fibrosis/cirrhosis because it acts through multiple mechanisms, including immunomodulation, anti-fibrotic signaling, regeneration, and oxidative-stress control. It also finds that clinical evidence is encouraging overall, but efficacy varies and the field still needs standardized production, delivery, and dosing protocols.
## Key findings
- The authors systematically searched ClinicalTrials.gov through August 27, 2025 and identified 95 clinical trials of cell therapy for liver cirrhosis/fibrosis; 73 of these focused on MSCs.
- Across the clinical trials reviewed, none reported severe adverse events related to MSC therapy; the most common side effect was fever, which was manageable with antipyretics.
- In the largest cited randomized controlled Phase II study, 219 patients with HBV-related decompensated liver cirrhosis received 0.5 × 10^6 allogeneic UC-MSCs/kg intravenously on three occasions at 4-week intervals and had a significantly higher overall survival rate from 13 to 75 months, with improved ALB, PTA, CHE, and TBIL over 48 weeks.
- Another China trial with 201 patients with decompensated liver cirrhosis reported a significantly higher overall survival rate after MSC therapy during a 5-year follow-up.
- The review highlights that MSCs can attenuate fibrosis by blocking hepatic stellate cells, promoting ECM degradation/remodeling, enhancing hepatocyte proliferation, and reducing oxidative stress.
## Methods
- Narrative review plus systematic clinical-trial search: the authors searched ClinicalTrials.gov from inception to August 27, 2025 for trials of “cell” treatment for “liver cirrhosis OR liver fibrosis.”
- They extracted trial characteristics including NCT number, phase, status, country, cell source, administration route, and main results, then categorized and visualized the findings.
- They also synthesized preclinical and clinical literature on mechanisms and efficacy, with special attention to MSCs.
## Limitations
- The paper states that there is no consensus on several core clinical parameters, including cell source, preparation, delivery route, and dose, which makes trial results heterogeneous.
- It states that many findings are still based on animal studies or early-phase trials, and that further research is needed to confirm mechanisms and optimize clinical use.
- Evident from the text: the clinical evidence base is limited by variable study design, incomplete posted results, and differing follow-up durations, and the review itself is not a new interventional study (this is evident from the text).
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 3 Clinical trials of cell therapy for liver cirrhosis. A An overall of clinical trials of cell therapy for liver cirrhosis classified by cell type. B Clinical trials of MSC and MSC combined therapy for liver cirrhosis. C Clinical trials of MSC combined therapy for liver cirrhosis. D Clinical trials of MSC therapy for liver cirrhosis classified by country. E Clinical trials of MSC therapy for liver cirrhosis classified by phase. F Clinical trials of MSC therapy for liver cirrhosis classified by status. G Clinical trials of liver fibrosis based on autologous and allogeneic transplantation of MSCs. H Clinical trials of liver fibrosis based on different sources of MSCs. I Clinical trials of liver fibrosis based on delivery routes of MSCs. J Clinical trials of MSC-EV-related therapy for liver cirrhosis. The data showed the number of corresponding clinical trials registered on https://clinicaltrials.gov/ [270]. Abbreviations: MSC: mesenchymal stromal cell. Created with GraphPad Prism 10.2.3 (GraphPad Software, CA, USA)](https://figures.cochat.ai/paper-figures/c4170ecdf95d4d73b6a3b13a9f9fa766/mechanisms-efficacy-and-future-perspectives-of-cellular-based-therapies-for-figure-3.jpg)

Verification
Claims the paper makes
158 Valid · 5 Not valid · 91 Not checked · 52 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Nevertheless, unlike findings from animal experiments, human studies did not show favorable results regarding liver function, fibrosis, or survival rates [37–39].”
§ Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells > Cell types used in the treatment of liver fibrosis/cirrhosis > Hepatocytes
What the sources say
- Not checked — no full text of the sourcecites [37] El Baz H, Demerdash Z, Kamel M, Atta S, Salah F, Hassan S, et al. Transplant of hepatocytes, undifferentiated mesenchymal stem cells, and in vitro hepatocyte-differentiated mesenchymal stem cells in a chronic liver failure experimental model: a comparative study. Exp Clin Transplant. 2018;16:81–9. https://doi.org/10.6002/ect.2016.0226. source
- Disputedcites [38] Hendrawan S, Lheman J, Nuraeni S, Weber U, Baer HU. Hepatocyte and islet cell cotransplantation on poly-L-lactide matrix for the treatment of liver cirrhosis. Int J Hepatol. 2020;2020:5410359. https://doi.org/10.1155/2020/5410359. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) describes clinical results as encouraging and reports significant improvement in liver function and general health in nine of ten patients in a German study. That contradicts the attributed claim that human studies showed no favorable results. This paper does not establish the claimed lack of benefit for fibrosis or survival either. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [39] Pinheiro D, Dias I, Silva KR, Stumbo AC, Thole A, Cortez E, et al. Mechanisms underlying cell therapy in liver fibrosis: an overview. Cells. 2019;8:1339. https://doi.org/10.3390/cells8111339. sourceExperimental — accuracy not yet measured
Section 2.6 (page not available) says hepatocyte transplantation produced better overall results in animal models than in humans, supporting the comparison. But it also reports several months of disease regression in human recipients and does not establish that human studies showed no favorable results for liver function, fibrosis, or survival rates. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a recent clinical trial, human autologous hepatocytes were co-cultured with islet cells onto a 3D porous poly-L-lactic acid scaffold and subsequently re-implanted into the mesentery leaves of patients with LC, resulting in improved model for end-stage liver disease (MELD) scores and liver-related blood values [38].”
§ Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells > Cell types used in the treatment of liver fibrosis/cirrhosis > Hepatocytes
What the sources say
- Partly supportedcites [38] Hendrawan S, Lheman J, Nuraeni S, Weber U, Baer HU. Hepatocyte and islet cell cotransplantation on poly-L-lactide matrix for the treatment of liver cirrhosis. Int J Hepatol. 2020;2020:5410359. https://doi.org/10.1155/2020/5410359. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“However, a decline in albumin (ALB) and cholinesterase (CHE) levels toward the end of the study was noted, leading to speculation about the maintenance of cell viability and functionality.”
§ Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells > Cell types used in the treatment of liver fibrosis/cirrhosis > Hepatocytes
What the sources say
- Could not verifycites [38] Hendrawan S, Lheman J, Nuraeni S, Weber U, Baer HU. Hepatocyte and islet cell cotransplantation on poly-L-lactide matrix for the treatment of liver cirrhosis. Int J Hepatol. 2020;2020:5410359. https://doi.org/10.1155/2020/5410359. sourceExperimental — accuracy not yet measured
The Results section says that clinical outcomes and laboratory parameters were reported in an earlier publication, but our copy does not give albumin or cholinesterase trends. Searches for albumin, cholinesterase, ALB, and CHE found no passage documenting a decline toward the end of the study. Page numbers were not available in our copy. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These aHSCs subsequently migrate to the site of injury, where they secrete fibrogenic components of ECM [e.g., collagen type I α1, tissue inhibitors of metalloproteinase (TIMP)-1, and matrix metalloproteinase (MMP)-2] to encapsulate the injury for repair and maintain tissue integrity [1].”
§ Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells > Pathogenesis of liver fibrosis
What the sources say
- Partly supportedcites [1] Acharya P, Chouhan K, Weiskirchen S, Weiskirchen R. Cellular mechanisms of liver fibrosis. Front Pharmacol. 2021;12:671640. https://doi.org/10.3389/fphar.2021.671640. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says fibrogenic ECM is secreted to encapsulate damaged tissue for repair, and the Hepatic Stellate Cells and Myofibroblasts section identifies activated HSC-derived cells as collagen-secreting. The copy does not establish that activated HSCs migrate to the injury site or secrete TIMP-1 and MMP-2 as ECM components; its Portal Fibroblasts section mentions TIMP-1 as a myofibroblast marker. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the proliferation of liver parenchymal cells is hampered, especially in advanced fibrosis, LPCs may become activated and differentiate into mature hepatocytes and cholangiocytes, thereby facilitating repopulation and improving liver function [20, 41].”
§ Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells > Cell types used in the treatment of liver fibrosis/cirrhosis > Liver progenitor cells LPCs are quiescent cells located in the canals of Hering and have the advantages of wide availability and good cryopreservation. The fetal liver contains a greater number of LPCs, which demonstrate a strong capacity for proliferation and regeneration [40]. When the proliferation of liver parenchymal cells is hampered, especially in advanced fibrosis, LPCs may become activated and differentiate into mature hepatocytes and cholangiocytes, thereby facilitating repopulation and improving liver function [20, 41]. In a clinical trial, 25 patients with MELD scores exceeding 16 were infused with human fetal liver-derived EpCAM+ LPCs through the hepatic artery [20]. The six-month follow-up period revealed no complications related to the procedure while demonstrating significant improvements in MELD scores and levels of serum ALB, alkaline phosphatase (ALP), and bilirubin. In a murine model of LC, transplanted human fetal LPCs were engrafted into the liver, leading to improvements in fibrosis, nodular formation, and clinical manifestations of cirrhosis, including hypoalbuminemia, hyperbilirubinemia, and coagulopathy [42]. However, LPCs have also been reported to promote fibrosis by either differentiating into MFs or releasing cytokines that activate qHSCs, raising doubts about their safety and efficacy [43–45]. Another major obstacle for the use of LPCs is their poor engraftment. Three days after transplantation, most LPCs were located within the portal vein and underwent apoptosis, constituting less than 0.01% of total hepatocytes [46].
What the sources say
- Not checked — no full text of the sourcecites [20] Khan AA, Shaik MV, Parveen N, Rajendraprasad A, Aleem MA, Habeeb MA, et al. Human fetal liver-derived stem cell transplantation as supportive modality in the management of end-stage decompensated liver cirrhosis. Cell Transplant. 2010;19:409–18. https://doi.org/10.3727/096368910X498241. source
- Partly supportedcites [41] Tao Y-C, Chen E-Q. Clinical application of stem cell in patients with end-stage liver disease: progress and challenges. Ann Trans Med. 2020;8:564–564. https://doi.org/10.21037/atm.2020.03.153. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible causen = 25- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
163 more claims · 82 with their cited sources checked
Create a free account to see all 306 claims and to verify the 42 references still open.
- Probably not a substantial claim. 19
- It may state two separate claims as one. 128
- The quote only partly states this claim. 1
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052 · cited 1×
“BM-MSCs were the first identified and the most commonly studied MSCs in pre-clinical and clinical studies [311].”
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766 · cited 1×
“…adherence, 2) trilin-eage mesenchymal differentiation potential (osteoblasts, chondrocytes, and adipocytes), and 3) specific surface marker expression [e.g., positive for CD105, CD73, and CD90; and negative for CD34, CD45, CD14 or CD11b, CD79α or CD19, and human leucocyte antigen (HLA)- DR] [28].”
Isolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725 · cited 1×
“EPCs, as initially characterized by Asahara et al. in 1997, represent a small, heterogeneous progenitor cell population originating from bone marrow or peripheral blood, encompassing both early EPCs [myeloid angiogenic cells (MACs)] and late EPCs [endothelial colony-forming cells (ECFCs)] [68–70].”
Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies
Zuk, P. A., Zhu, M., Mizuno, H., Huang, J., Futrell, J. W., Katz, A. J., Benhaim, P., Lorenz, H. P., & Hedrick, M. H. (2001) · Tissue Engineering · doi:10.1089/107632701300062859 · Cited by 7,956 · cited 1×
“…have been obtained from various sources with similar in vitro properties, including tissues and secretion of adult body such as adipose tissue (AT) [29], synovial membrane [30], ligament [31], peripheral blood (PB), menstrual blood (MB), dental pulp, and breast milk, as well as fetal tissues such…”
Caplan, A. I. (1991) · Journal of Orthopaedic Research · doi:10.1002/jor.1100090504 · Cited by 6,548
The M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689 · cited 1×
“Conversely, M2 cells, alternatively activated by IL-4, IL-10, IL-13, TGF-β, and immune complexes, exhibit a more anti-inflammatory phenotype and promote the fibrosis resolution [77].”
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511 · cited 1×
“MSCs can inhibit the proliferation of T cells and induce the apoptosis of activated T cells through direct interaction or by releasing several mediators, including TGF-β, HGF, IDO, and PGE2 [132, 159, 160].”
Investigation of multipotent postnatal stem cells from human periodontal ligament
Seo, B.-M., Miura, M., Gronthos, S., Mark Bartold, P., Batouli, S., Brahim, J., Young, M., Gehron Robey, P., Wang, C. Y., & Shi, S. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16627-0 · Cited by 3,546 · cited 1×
“…with similar in vitro properties, including tissues and secretion of adult body such as adipose tissue (AT) [29], synovial membrane [30], ligament [31], peripheral blood (PB), menstrual blood (MB), dental pulp, and breast milk, as well as fetal tissues such as umbilical cord (UC), Wharton’s jelly…”
Kowal, J., Arras, G., Colombo, M., Jouve, M., Morath, J. P., Primdal-Bengtson, B., Dingli, F., Loew, D., Tkach, M., & Théry, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521230113 · Cited by 3,426 · cited 1×
“Most mitochondrial components have been reported to fractionate in larger EVs by proteomic analysis [395].”
Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226 · cited 3×
“BM-MSCs inhibit the proliferation of CD4 + and CD8 + T cells induced by DCs or humoral stimuli through the synergistic effect of TGF-β and HGF [132].”
Research works printed but not linked: 4
- Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, Bagheri M, Bashtar M, Ghanaati H, et al. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med. 2007;10:459–66.
- Nikeghbalian S, Pournasr B, Aghdami N, Rasekhi A, Geramizadeh B, Hosseini Asl SMK, et al. Autologous transplantation of bone marrow-derived mononuclear and CD133(+) cells in patients with decompensated cirrhosis. Arch Iran Med. 2011;14:12–7.
- Picardi M, De Rosa G, Selleri C, Scarpato N, Soscia E, Martinelli V, et al. Spleen enlargement following recombinant human granulocyte colony-stimulating factor administration for peripheral blood stem cell mobilization. Haematologica. 2003;88:794–800.
- Vosough M, Moossavi S, Mardpour S, Akhlaghpoor S, Azimian V, Jarughi N, et al. Repeated intraportal injection of mesenchymal stem cells in combination with pioglitazone in patients with compensated cirrhosis: a clinical report of two cases. Arch Iran Med. 2016;19:131–6.
Cited by
Feng, L., He, J., Mu, Y., (15128), J. L., & Yao, Y. (2026) · PLoS ONE · doi:10.1371/journal.pone.0350886
Mitochondrial transfer in solid tumors: dual roles in tumor progression and therapeutic targeting
Huang, L., Li, Z., Qin, C., Zhao, B., Li, T., Zhao, Y., Shi, H., Zhang, X., Xie, Y., Yan, Y., et al. (2026) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2026.68
Metadata
- Authors
- Pan, X., Gao, T., & Wang, B.
- Affiliations
- Nanjing Normal University (CN)
- Nanjing Drum Tower Hospital (CN)
- Corresponding author
- Wang, Bin
- Venue
- Cell & Bioscience
- Published
- 2025-12-30
- Volume
- 16
- Issue
- 1
- Pages
- 11-11
- ISSN
- 2045-3701 (ISSN-L)
- PMC
- PMC12860015
- OpenAlex
- W7117538003
- Cited by
- 2
- References
- 405
- Citations by year
- 2026: 2
- FWCI
- 0.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor, 31 d)
- Locations
- Cell & Bioscience (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82070459, 82270701)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- liver fibrosis, liver cirrhosis, mesenchymal stem cells, cell therapy, extracellular matrix remodeling, hepatic stellate cells, hepatocyte regeneration, oxidative stress, immunomodulation, cell delivery routes, biomaterials engineering, endothelial progenitor cells, macrophages, organoids, single-cell analysis, MSC heterogeneity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells. https://app.cochat.ai/papers/10.1186/s13578-025-01520-9
- The paper
- Pan, X., Gao, T., & Wang, B. (2025). Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells. Cell & Bioscience. https://doi.org/10.1186/s13578-025-01520-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.